Genome Medicine | All articles

Explore this journal

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

		Research A whole genome association study of mother-to-child transmission of HIV in Malawi Bonnie R Joubert, Ethan M Lange, Nora Franceschini, Victor Mwapasa, Kari E North, Steven R Meshnick, The NIAID Center for HIV/AIDS Vaccine Immunology Genome Medicine 2010, 2:17 (1 March 2010) Abstract \| Provisional PDF \| Editor’s summary Mother-to-child HIV transmission in Malawian infants is associated with nine single nucleotide polymorphisms in six genes with roles in pregnancy, development, innate immunity and HIV-protein interaction.
		Database Collaboratively charting the gene-to-phenotype network of human congenital heart defects Roland Barriot, Jeroen Breckpot, Bernard Thienpont, Sylvain Brohée, Steven Van Vooren, Bert Coessens, Leon-Charles Tranchevent, Peter Van Loo, Marc Gewillig, Koenraad Devriendt, Yves Moreau Genome Medicine 2010, 2:16 (1 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The development of a specialized portal for collaborative annotation and analysis of gene-phenotype networks in congenital heart defects using a Wiki platform highlights this technology’s potential for systems biology studies of other complex biological processes.
		Review Coping with antibiotic resistance: contributions from genomics Gian Rossolini, Maria Thaller Genome Medicine 2010, 2:15 (25 February 2010) Abstract \| Full text \| PDF \| Editor’s summary Bacterial genomics is helping to tackle antibiotic resistance by identifying new targets and increasing our understanding of resistance mechanisms.
		Commentary Developmental origins of health and disease: reducing the burden of chronic disease in the next generation Peter D Gluckman, Mark A Hanson, Murray D Mitchell Genome Medicine 2010, 2:14 (24 February 2010) Abstract \| Full text \| PDF \| Editor’s summary There is an unwillingness among public health decision makers to implement approaches based on evidence that environmental factors in early life can affect disease vulnerability in later life.
		Meeting report Pharmacogenomics and personalized medicine: lost in translation? Jean-Sébastien Hulot Genome Medicine 2010, 2:13 (22 February 2010) Abstract \| Full text \| PDF \| Editor’s summary A report on the Joint Cold Spring Harbor/Wellcome Trust Conference 'Pharmacogenomics & Personalized Medicine', Hinxton, UK, 12-15 September 2009.
		Review Non-coding RNAs: a key to future personalized molecular therapy? Marco Galasso, Maria Elena Sana, Stefano Volinia Genome Medicine 2010, 2:12 (18 February 2010) Abstract \| Full text \| PDF \| Editor’s summary Non-coding RNAs such as microRNAs and small nucleolar RNAs are implicated in human diseases ranging from cancer to neurodegenerative and metabolic diseases and offer new avenues for the development of non-invasive diagnostics and molecular therapies.
		Review Inversion variants in the human genome: role in disease and genome architecture Lars Feuk Genome Medicine 2010, 2:11 (12 February 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary While paired-end sequencing approaches have allowed the identification and mapping of inversions across the human genome, further characterization of inversion variants is required to advance our understanding of human variation and genome dynamics.
		Research Multi-locus models of genetic risk of disease Naomi R Wray, Michael E Goddard Genome Medicine 2010, 2:10 (2 February 2010) Abstract \| Provisional PDF \| PubMed \| Editor’s summary The widely accepted unconstrained multiplicative model which combines genome wide association data for overall risk calculation is not realistic, while other models more compatible with the data are indistinguishable using currently available observed parameters.
		Research *Integration of microRNA changes in vivo* identifies novel molecular features of muscle insulin resistance in type 2 diabetes** Iain J Gallagher, Camilla Scheele, Pernille Keller, Anders R Nielsen, Judit Remenyi, Christian P Fischer, Karim Roder, John Babraj, Claes Wahlestedt, Gyorgy Hutvagner, Bente K Pedersen, James A Timmons Genome Medicine 2010, 2:9 (1 February 2010) Abstract \| Full text \| PDF \| Editor’s summary Muscle mRNA expression is invariant with respect to diabetes status, but coordinated changes in numerous microRNAs may control protein abundance and affect skeletal muscle insulin resistance, a critical component of the disease.
		Review Downstream EWS/FLI1 - upstream Ewing's sarcoma Heinrich Kovar Genome Medicine 2010, 2:8 (28 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ewing's sarcoma family tumors express the fusion protein EWS/FLI1, modulation of which is a desirable therapeutic goal.
		Musings Musings on genome medicine: Hepatitis C David G Nathan, Stuart H Orkin Genome Medicine 2010, 2:4 (27 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent advances in our understanding of the genetics of response to interferon treatment are intriguing, but further research is necessary before we can achieve a true cure for hepatitis C.
		Review Recent advances in the genetics of language impairment Dianne F Newbury, Simon E Fisher, Anthony P Monaco Genome Medicine 2010, 2:6 (26 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Four genes involved in specific language impairment have now been identified, highlighting a variety of neural pathways which contribute to the disorder.
		Meeting report Genome informatics: advances in theory and practice Szu-chin Fu, Paul Horton Genome Medicine 2010, 2:7 (26 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A report on the 20th International Conference on Genome Informatics, Yokohama, Japan, 14-16 December 2009.
		Review Genomic variants associated with primary biliary cirrhosis Carlo Selmi, Natalie J Torok, Andrea Affronti, M Eric Gershwin Genome Medicine 2010, 2:5 (26 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Association of primary biliary cirrhosis with many genetic variants has not greatly improved our understanding of the disease, but epigenomic and microRNA research may provide more answers.
		Commentary The 1000 Genomes Project: new opportunities for research and social challenges Marc Via, Christopher Gignoux, Esteban Burchard Genome Medicine 2010, 2:3 (21 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Safeguarding against ethical and privacy concerns will help clinical research to benefit from the 1000 Genomes Project.
		Method Family-based genetic risk prediction of multifactorial disease Douglas M Ruderfer, Joshua Korn, Shaun M Purcell Genome Medicine 2010, 2:2 (15 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Inclusion of phenotypic and genotypic information from close relatives in a genetic risk prediction model can lead to improved estimates of an individual’s disease risk.
		Research Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia Nathan A Stephens, Iain J Gallagher, Olav Rooyackers, Richard J Skipworth, Ben H Tan, Troels Marstrand, James A Ross, Denis C Guttridge, Lars Lundell, Kenneth C Fearon, James A Timmons Genome Medicine 2010, 2:1 (15 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An 83-gene signature for cachexia in cancer patients includes genes such as CaMKII and TIE1 and suggests that preclinical models do not accurately reflect biological processes in human cancer cachexia.
		Review What lies behind serum urate concentration? Insights from genetic and genomic studies Kimiyoshi Ichida Genome Medicine 2009, 1:118 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent genome-wide studies have identified novel candidate genes related to urate metabolism and transport, but their physiological roles and the influence of environmental factors remain unclear.
		Review Pharmacogenomic insights into treatment and management of statin-induced myopathy Bas JM Peters, Olaf H Klungel, Frank L Visseren, Anthonius de Boer, Anke-Hilse Maitland-van der Zee Genome Medicine 2009, 1:120 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin by reducing the chance of developing this rare but serious side-effect.
		Commentary Human genomics and preparedness for infectious threats Nicole F Dowling, Marta Gwinn, Alison Mawle Genome Medicine 2009, 1:119 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Research activity during infectious disease outbreaks maximizes limited resources, enhances gains in scientific knowledge, and ultimately increases levels of preparedness.
		Research Postmenopausal estrogen and progestin effects on the serum proteome Sharon J Pitteri, Samir M Hanash, Aaron Aragaki, Lynn M Amon, Lin Chen, Tina Busald Buson, Sophie Paczesny, Hiroyuki Katayama, Hong Wang, Melissa M Johnson, Qing Zhang, Martin McIntosh, Pei Wang, Charles Kooperberg, Jacques E Rossouw, Rebecca D Jackson, JoAnn E Manson, Judith Hsia, Simin Liu, Lisa Martin, Ross L Prentice Genome Medicine 2009, 1:121 (24 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Estrogen plus progestin and estrogen-alone have different effects on proteins involved in growth factor and inflammation pathways, providing an explanation for the distinctive clinical effects of each therapy.
		Minireview *Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility* Wolfgang Sadee Genome Medicine 2009, 1:116 (22 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A recent large-scale allelic expression analysis shows that cis-acting regulatory variants might reveal some of the 'missing heritability' component of complex disorders, which could lead to potential therapy and prevention breakthroughs.
		Review Metabolic adaptation of skeletal muscle to high altitude hypoxia: how new technologies could resolve the controversies Andrew J Murray Genome Medicine 2009, 1:117 (18 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An integrated and quantitative understanding of the body’s metabolic response to high altitude and the conditions under which adaptive processes occur could reveal much about the ways that tissues function in disease states where hypoxia is a critical factor.
		Musings Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases David G Nathan, Stuart H Orkin Genome Medicine 2009, 1:114 (9 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Enzyme replacement therapies are costly and incomplete but may save lives until more effective therapy is developed, however preventive strategies such as carrier detection should be considered for future management of rare lysosomal storage diseases.
		Research Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor δ from Peroxisome proliferator-activated receptor γ in the ob/ob mouse Lee D Roberts, David G Hassall, Deborah A Winegar, John N Haselden, Andrew W Nicholls, Julian L Griffin Genome Medicine 2009, 1:115 (7 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Peroxisome proliferator-activated receptor (PPAR) delta plays a distinct catabolic role by activating hepatic and peripheral fatty acid oxidative metabolism, highlighting its potential as a therapeutic target for dyslipidaemia and metabolic syndrome.

		Research A whole genome association study of mother-to-child transmission of HIV in Malawi Bonnie R Joubert, Ethan M Lange, Nora Franceschini, Victor Mwapasa, Kari E North, Steven R Meshnick, The NIAID Center for HIV/AIDS Vaccine Immunology Genome Medicine 2010, 2:17 (1 March 2010) Abstract \| Provisional PDF \| Editor’s summary Mother-to-child HIV transmission in Malawian infants is associated with nine single nucleotide polymorphisms in six genes with roles in pregnancy, development, innate immunity and HIV-protein interaction.
		Database Collaboratively charting the gene-to-phenotype network of human congenital heart defects Roland Barriot, Jeroen Breckpot, Bernard Thienpont, Sylvain Brohée, Steven Van Vooren, Bert Coessens, Leon-Charles Tranchevent, Peter Van Loo, Marc Gewillig, Koenraad Devriendt, Yves Moreau Genome Medicine 2010, 2:16 (1 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The development of a specialized portal for collaborative annotation and analysis of gene-phenotype networks in congenital heart defects using a Wiki platform highlights this technology’s potential for systems biology studies of other complex biological processes.
		Review Coping with antibiotic resistance: contributions from genomics Gian Rossolini, Maria Thaller Genome Medicine 2010, 2:15 (25 February 2010) Abstract \| Full text \| PDF \| Editor’s summary Bacterial genomics is helping to tackle antibiotic resistance by identifying new targets and increasing our understanding of resistance mechanisms.
		Commentary Developmental origins of health and disease: reducing the burden of chronic disease in the next generation Peter D Gluckman, Mark A Hanson, Murray D Mitchell Genome Medicine 2010, 2:14 (24 February 2010) Abstract \| Full text \| PDF \| Editor’s summary There is an unwillingness among public health decision makers to implement approaches based on evidence that environmental factors in early life can affect disease vulnerability in later life.
		Meeting report Pharmacogenomics and personalized medicine: lost in translation? Jean-Sébastien Hulot Genome Medicine 2010, 2:13 (22 February 2010) Abstract \| Full text \| PDF \| Editor’s summary A report on the Joint Cold Spring Harbor/Wellcome Trust Conference 'Pharmacogenomics & Personalized Medicine', Hinxton, UK, 12-15 September 2009.
		Review Non-coding RNAs: a key to future personalized molecular therapy? Marco Galasso, Maria Elena Sana, Stefano Volinia Genome Medicine 2010, 2:12 (18 February 2010) Abstract \| Full text \| PDF \| Editor’s summary Non-coding RNAs such as microRNAs and small nucleolar RNAs are implicated in human diseases ranging from cancer to neurodegenerative and metabolic diseases and offer new avenues for the development of non-invasive diagnostics and molecular therapies.
		Review Inversion variants in the human genome: role in disease and genome architecture Lars Feuk Genome Medicine 2010, 2:11 (12 February 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary While paired-end sequencing approaches have allowed the identification and mapping of inversions across the human genome, further characterization of inversion variants is required to advance our understanding of human variation and genome dynamics.
		Research Multi-locus models of genetic risk of disease Naomi R Wray, Michael E Goddard Genome Medicine 2010, 2:10 (2 February 2010) Abstract \| Provisional PDF \| PubMed \| Editor’s summary The widely accepted unconstrained multiplicative model which combines genome wide association data for overall risk calculation is not realistic, while other models more compatible with the data are indistinguishable using currently available observed parameters.
		Research *Integration of microRNA changes in vivo* identifies novel molecular features of muscle insulin resistance in type 2 diabetes** Iain J Gallagher, Camilla Scheele, Pernille Keller, Anders R Nielsen, Judit Remenyi, Christian P Fischer, Karim Roder, John Babraj, Claes Wahlestedt, Gyorgy Hutvagner, Bente K Pedersen, James A Timmons Genome Medicine 2010, 2:9 (1 February 2010) Abstract \| Full text \| PDF \| Editor’s summary Muscle mRNA expression is invariant with respect to diabetes status, but coordinated changes in numerous microRNAs may control protein abundance and affect skeletal muscle insulin resistance, a critical component of the disease.
		Review Downstream EWS/FLI1 - upstream Ewing's sarcoma Heinrich Kovar Genome Medicine 2010, 2:8 (28 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ewing's sarcoma family tumors express the fusion protein EWS/FLI1, modulation of which is a desirable therapeutic goal.
		Musings Musings on genome medicine: Hepatitis C David G Nathan, Stuart H Orkin Genome Medicine 2010, 2:4 (27 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent advances in our understanding of the genetics of response to interferon treatment are intriguing, but further research is necessary before we can achieve a true cure for hepatitis C.
		Review Recent advances in the genetics of language impairment Dianne F Newbury, Simon E Fisher, Anthony P Monaco Genome Medicine 2010, 2:6 (26 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Four genes involved in specific language impairment have now been identified, highlighting a variety of neural pathways which contribute to the disorder.
		Meeting report Genome informatics: advances in theory and practice Szu-chin Fu, Paul Horton Genome Medicine 2010, 2:7 (26 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A report on the 20th International Conference on Genome Informatics, Yokohama, Japan, 14-16 December 2009.
		Review Genomic variants associated with primary biliary cirrhosis Carlo Selmi, Natalie J Torok, Andrea Affronti, M Eric Gershwin Genome Medicine 2010, 2:5 (26 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Association of primary biliary cirrhosis with many genetic variants has not greatly improved our understanding of the disease, but epigenomic and microRNA research may provide more answers.
		Commentary The 1000 Genomes Project: new opportunities for research and social challenges Marc Via, Christopher Gignoux, Esteban Burchard Genome Medicine 2010, 2:3 (21 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Safeguarding against ethical and privacy concerns will help clinical research to benefit from the 1000 Genomes Project.
		Method Family-based genetic risk prediction of multifactorial disease Douglas M Ruderfer, Joshua Korn, Shaun M Purcell Genome Medicine 2010, 2:2 (15 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Inclusion of phenotypic and genotypic information from close relatives in a genetic risk prediction model can lead to improved estimates of an individual’s disease risk.
		Research Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia Nathan A Stephens, Iain J Gallagher, Olav Rooyackers, Richard J Skipworth, Ben H Tan, Troels Marstrand, James A Ross, Denis C Guttridge, Lars Lundell, Kenneth C Fearon, James A Timmons Genome Medicine 2010, 2:1 (15 January 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An 83-gene signature for cachexia in cancer patients includes genes such as CaMKII and TIE1 and suggests that preclinical models do not accurately reflect biological processes in human cancer cachexia.
		Review What lies behind serum urate concentration? Insights from genetic and genomic studies Kimiyoshi Ichida Genome Medicine 2009, 1:118 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent genome-wide studies have identified novel candidate genes related to urate metabolism and transport, but their physiological roles and the influence of environmental factors remain unclear.
		Review Pharmacogenomic insights into treatment and management of statin-induced myopathy Bas JM Peters, Olaf H Klungel, Frank L Visseren, Anthonius de Boer, Anke-Hilse Maitland-van der Zee Genome Medicine 2009, 1:120 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin by reducing the chance of developing this rare but serious side-effect.
		Commentary Human genomics and preparedness for infectious threats Nicole F Dowling, Marta Gwinn, Alison Mawle Genome Medicine 2009, 1:119 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Research activity during infectious disease outbreaks maximizes limited resources, enhances gains in scientific knowledge, and ultimately increases levels of preparedness.
		Research Postmenopausal estrogen and progestin effects on the serum proteome Sharon J Pitteri, Samir M Hanash, Aaron Aragaki, Lynn M Amon, Lin Chen, Tina Busald Buson, Sophie Paczesny, Hiroyuki Katayama, Hong Wang, Melissa M Johnson, Qing Zhang, Martin McIntosh, Pei Wang, Charles Kooperberg, Jacques E Rossouw, Rebecca D Jackson, JoAnn E Manson, Judith Hsia, Simin Liu, Lisa Martin, Ross L Prentice Genome Medicine 2009, 1:121 (24 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Estrogen plus progestin and estrogen-alone have different effects on proteins involved in growth factor and inflammation pathways, providing an explanation for the distinctive clinical effects of each therapy.
		Minireview *Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility* Wolfgang Sadee Genome Medicine 2009, 1:116 (22 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A recent large-scale allelic expression analysis shows that cis-acting regulatory variants might reveal some of the 'missing heritability' component of complex disorders, which could lead to potential therapy and prevention breakthroughs.
		Review Metabolic adaptation of skeletal muscle to high altitude hypoxia: how new technologies could resolve the controversies Andrew J Murray Genome Medicine 2009, 1:117 (18 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An integrated and quantitative understanding of the body’s metabolic response to high altitude and the conditions under which adaptive processes occur could reveal much about the ways that tissues function in disease states where hypoxia is a critical factor.
		Musings Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases David G Nathan, Stuart H Orkin Genome Medicine 2009, 1:114 (9 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Enzyme replacement therapies are costly and incomplete but may save lives until more effective therapy is developed, however preventive strategies such as carrier detection should be considered for future management of rare lysosomal storage diseases.
		Research Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor δ from Peroxisome proliferator-activated receptor γ in the ob/ob mouse Lee D Roberts, David G Hassall, Deborah A Winegar, John N Haselden, Andrew W Nicholls, Julian L Griffin Genome Medicine 2009, 1:115 (7 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Peroxisome proliferator-activated receptor (PPAR) delta plays a distinct catabolic role by activating hepatic and peripheral fatty acid oxidative metabolism, highlighting its potential as a therapeutic target for dyslipidaemia and metabolic syndrome.